Eisai Press Release


FDA Accepts Eisai's Filing of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease
Jun 10, 2024 17:50 JST
Eisai Co., Ltd. and Biogen Inc. announced today that that the U.S. Food and Drug Administration (FDA) has accepted Eisai's Supplemental Biologics License Application (sBLA) for monthly lecanemab-irmb (U.S. brand name: LEQEMBI) intravenous (IV) maintenance dosing.
More info..

Eisai Named to List of The Time 100 Most Influential Companies
Jun 03, 2024 16:08 JST
TIME reveals the TIME100 Most Influential Companies list, highlighting companies making an extraordinary impact around the world.
More info..

Eisai Strengthens Venture Investment Business Aimed at Accelerating Drug Discovery Innovation and Establishment of Ecosystem Platform
Jun 03, 2024 14:22 JST
Eisai Co., Ltd. announced today that the company decided to strengthen and continue its venture investment business, which launched in 2019, with the aim of discovering innovative technologies and services, supporting venture businesses with such technologies and partnering with those businesses in the future, so as to accelerate drug discovery innovation and the establishment of the ecosystem platform.
More info..

LEQEMBI (lecanemab) Approved for the Treatment of Alzheimer's Disease in South Korea
May 28, 2024 14:19 JST
Eisai Co., Ltd. and Biogen Inc. announced today that the Ministry of Food and Drug Safety (MFDS) in South Korea has approved humanized anti-soluble aggregated amyloid-beta (Abeta) monoclonal antibody "LEQEMBI" (lecanemab) for treatment in adult patients with mild cognitive impairment due to Alzheimer's disease (AD) or mild AD (early AD).
More info..

Eisai Showcases Oncology Portfolio and Pipeline at ASCO 2024
May 23, 2024 17:07 JST
Eisai Co., Ltd. announced today the presentation of research across multiple types of cancer from its oncology portfolio and pipeline during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO24), which is taking place virtually and in-person in Chicago, Illinois from May 31 to June 4.
More info..

Eisai: Metoject Subcutaneous Injection Pen (Methotrexate) Pen-Type Autoinjector Launched In Japan
May 22, 2024 11:55 JST
Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac group announced today that they have launched the anti-rheumatic agent "Metoject Subcutaneous Injection 7.5mg Pen 0.15mL, 10mg Pen 0.20mL, 12.5mg Pen 0.25mL and 15mg Pen 0.30mL" (methotrexate, "MTX"), in Japan.
More info..

Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status
May 15, 2024 10:19 JST
LEQEMBI is indicated for the treatment of Alzheimer's disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD).
More info..

Eisai's Antiepileptic Drug Fycompa Approved in China for Adjunctive Treatment of Primary Generalized Tonic-Clonic Seizures
May 13, 2024 16:06 JST
Eisai Co., Ltd. announced today that it has received approval in China for the additional indication of its in-house discovered antiepileptic drug (AED) Fycompa (generic name: perampanel hydrate) for adjunctive treatment of primary generalized tonic-clonic seizures in patients with epilepsy aged 12 years and older.
More info..

Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category)
Apr 18, 2024 09:53 JST
Eisai Co., Ltd. announced today that "The Research on Treatments for Alzheimer's Disease Based on its Pathological Mechanisms" has received the Award for Science and Technology (Research Category) as a part of the FY2024 Commendation for Science and Technology by the Minister of Education, Culture, Sports, Science and Technology.
More info..

Eisai's Antiepileptic Drug Fycompa Injection Formulation Launched In Japan
Apr 17, 2024 15:17 JST
Eisai Co., Ltd. announced today that the injection formulation of its in-house discovered antiepileptic drug (AED) Fycompa (perampanel hydrate) for intravenous (IV) infusion has been launched in Japan.
More info..

French Sales Subsidiary Eisai S.A.S. to Divest Rights for Loxapac And Parkinane LP to CNX Therapeutics
Apr 03, 2024 15:24 JST
Eisai Co., Ltd. announced today that its French sales subsidiary Eisai S.A.S. entered into an agreement to transfer the rights in France, the French Overseas Territories and Algeria (the "Territory") for the antipsychotic, "Loxapac" (generic name: loxapine) and the Parkinson's disease treatment "Parkinane LP" (generic name: trihexyphenidyl hydrochloride) to CNX Therapeutics Limited (Headquarters: London, UK, "CNX").
More info..

Eisai Completes Submission of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA
Apr 01, 2024 08:39 JST
Eisai Co., Ltd. and Biogen Inc. announced today that Eisai submitted to the U.S. Food andDrug Administration (FDA) a Supplemental Biologics License Application (sBLA) for monthly lecanemab-irmb (U.S. brand name: LEQEMBI) intravenous (IV) maintenance dosing.
More info..

Eisai to Divest Rights for Merislon and Myonal in Japan to Kaken Pharmaceutical
Mar 29, 2024 14:51 JST
Eisai Co., Ltd. announced today that it has entered into an agreement to divest its rights for vertigo and equilibrium disturbance treatment Merislon (generic name: betahistine mesilate) and muscle relaxant Myonal (generic name: eperisone hydrochloride) in Japan to Kaken Pharmaceutical Co., Ltd.
More info..

Eisai's Brain Health Self-Check Tool "NouKNOW" is Certified as "ME-BYO BRAND" by Kanagawa Prefecture
Mar 29, 2024 14:19 JST
Eisai Co., Ltd. announced today that "NouKNOW", Eisai's self-check tool for brain health, was certified as a "ME-BYO BRAND" by Kanagawa prefecture.
More info..

Eisai: Discovery Research on Dual Orexin Receptor Antagonist Lemborexant Honored with PSJ Award for Drug Research and Development 2024
Mar 29, 2024 13:32 JST
Eisai Co., Ltd. announced today that drug discovery research conducted on lemborexant (brand name: Dayvigo), the dual orexin receptor antagonist discovered by Eisai, has been honored with The Pharmaceutical Society of Japan (PSJ) Award for Drug Research and Development 2024 by the PSJ.
More info..

Lifenet and Eisai Co-Develop Dementia Insurance "be"
Mar 21, 2024 16:36 JST
LIFENET INSURANCE COMPANY and Eisai Co., Ltd. announced today that they have co-developed Dementia Insurance "be", a dementia insurance that supports early detection and treatment of dementia and mild cognitive impairment (hereafter, "MCI") as one of the initiatives under the capital and business alliance agreement concluded in August 2022 for collaboration in dementia and other areas.
More info..

Eisai Selected as a Nadeshiko Brand 2024 as a Listed Company Excelling in Promotion of Women in the Workplace
Mar 21, 2024 15:10 JST
Eisai Co., Ltd. announced today that it has been selected for the first time by the Ministry of Economy, Trade and Industry (METI) and the Tokyo Stock Exchange (TSE) as one of the Nadeshiko Brand 2024, as a listed company excelling in the promotion of women in the workplace.
More info..

Eisai Invests in C2N to Support Simplifying the Diagnosis of Early Alzheimer's Disease to Better Serve Patients
Mar 06, 2024 16:47 JST
Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. has decided to invest up to 15 million USD in C2N Diagnostics LLC to support C2N's efforts to expand the availability, accessibility, affordability and utilization of blood-based tests for the diagnosis of Alzheimer's disease (AD) in the U.S.
More info..

Eisai to Boost Initiatives on Greenhouse Gas Reduction, Aiming to Achieve Net Zero by 2050
Feb 21, 2024 14:26 JST
Eisai Co., Ltd. announced today that it has received approval to participate in the Japan Climate Initiative (JCI) Race to Zero Circle, which commits to achieve net zero* by 2050, as part of its mid- and long-term initiatives to reduce greenhouse gas (GHG) emissions.
More info..

Eisai Selected for 'Human Capital Leaders 2023' and 'Human Capital Management Gold Quality', Recognized as Company Committed to Excellent Management and Disclosure of Human Capital Initiatives
Feb 20, 2024 08:35 JST
Eisai Co., Ltd. announced today that it has been selected for "Human Capital Leaders 2023" and "Human Capital Management Gold Quality" in the "Human Capital Survey 2023" jointly conducted by HR Technology Consortium, HR Research Institute (ProFuture Inc.) and MS&AD InterRisk Research & Consulting, Inc.
More info..

Eisai: Metoject Subcutaneous Injection Pen (Methotrexate) Pen-Type Autoinjector Approved in Japan
Feb 16, 2024 08:31 JST
Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac Gesellschaft fur klinische Spezialpraparate mbH announced that they have obtained manufacturing and marketing approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the additional formulation of Metoject Subcutaneous Injection for the anti-rheumatic agent, pen-type autoinjector "Metoject Subcutaneous Injection 7.5mg Pen 0.15mL, 10mg Pen 0.20mL, 12.5mg Pen 0.25mL and 15mg Pen 0.30mL" (methotrexate).
More info..

Eisai Commences Fully-Fledged Business Activities at Pharma Sales Subsidiary in South Africa
Feb 01, 2024 17:04 JST
Eisai Co., Ltd. announced today that fully-fledged operations have begun at Eisai Pharmaceuticals Africa (Pty) Ltd, a pharmaceutical sales subsidiary recently established in Johannesburg, South Africa, and direct sales operations and business activities have commenced in Africa.
More info..

Eisai Submits New Drug Application for Mecobalamin Ultrahigh-Dose Formulation in Japan for the Indication of Amyotrophic Lateral Sclerosis
Jan 26, 2024 15:26 JST
Eisai Co., Ltd. announced today that it has submitted a New Drug Application (NDA) for ultrahigh-dose mecobalamin (development code: E0302) for the indication of amyotrophic lateral sclerosis (ALS) to the Pharmaceuticals and Medical Devices Agency (PDMA) in Japan.
More info..

Eisai: Antiepileptic Drug Fycompa Injection Formulation Approved in Japan
Jan 18, 2024 14:12 JST
Eisai Co., Ltd. announced today that it has obtained marketing authorization approval from the Japanese Ministry of Health, Labour and Welfare for the injection formulation of its in-house discovered antiepileptic drug (AED) Fycompa (perampanel) in Japan as an alternative therapy when oral administration is temporarily not possible.
More info..

Eisai Listed as a Global 100 Most Sustainable Corporation for the Eighth Time
Jan 17, 2024 16:08 JST
Eisai Co., Ltd. announced today that it has been listed in the 2024 Global 100 Most Sustainable Corporations in the World (Global 100), a global ranking by Canada-based media and investment advisory company, Corporate Knights, Inc.
More info..

Eisai Furthers Oncology Research Across Multiple Cancers at ASCO GI and ASCO GU 2024
Jan 16, 2024 09:25 JST
Eisai Co., Ltd. announced today the presentation of oncology research at two upcoming medical meetings taking place in-person in San Francisco, California and virtually.
More info..

Eisai: The Scientific Advisory Group (SAG) to Convene to Discuss the Marketing Authorization Application for lecanemab in the EU
Jan 11, 2024 15:33 JST
Eisai Co., Ltd. announced today that the Scientific Advisory Group (SAG) will convene to discuss the marketing authorization application (MAA) of lecanemab (generic name, brand name: LEQEMBI), which is currently under review by the European Medicines Agency (EMA).
More info..

Eisai: "LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in China

Jan 10, 2024 09:15 JST
Eisai Co., Ltd. and Biogen Inc. announced today that humanized anti- soluble aggregated amyloid-beta (Abeta) monoclonal antibody "LEQEMBI" (generic name: lecanemab-irmb) has been approved in China as a treatment of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD dementia.
More info..

Development of Prediction Model for Brain Amyloid-Beta Accumulation Using Wristband Sensor
Dec 29, 2023 13:30 JST
Oita University and Eisai Co., Ltd. (Eisai) hereby announce the development of the world's first machine learning model to predict amyloid beta (Abeta) accumulation in the brain using a wristband sensor.
More info..

Latest Release


More Latest Release >>